Evidence map›Paper›PMID 29434608›Full record

ArticleFrontiers in immunology2018

A Case of Type 2 Hypersensitivity to Rasburicase Diagnosed with a Natural Killer Cell Activation Assay.

Sébastien Viel, Rémi Pescarmona, Alexandre Belot, Audrey Nosbaum, Christine Lombard, Thierry Walzer, Frédéric Bérard

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. LeechWorld journal of gastroenterology · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sébastien VielLaboratoire d'Immunologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France.
Rémi PescarmonaLaboratoire d'Immunologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France.
Alexandre BelotCentre International de Recherche en Infectiologie, CIRI, INSERM U1111, CNRS UMR5308, Ecole Normale supérieure de Lyon, Université Claude Bernard Lyon I, Lyon, France.
Audrey NosbaumCentre International de Recherche en Infectiologie, CIRI, INSERM U1111, CNRS UMR5308, Ecole Normale supérieure de Lyon, Université Claude Bernard Lyon I, Lyon, France.
Christine LombardLaboratoire d'Immunologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France.
Thierry WalzerCentre International de Recherche en Infectiologie, CIRI, INSERM U1111, CNRS UMR5308, Ecole Normale supérieure de Lyon, Université Claude Bernard Lyon I, Lyon, France.
Frédéric BérardCentre International de Recherche en Infectiologie, CIRI, INSERM U1111, CNRS UMR5308, Ecole Normale supérieure de Lyon, Université Claude Bernard Lyon I, Lyon, France.
Université Claude Bernard Lyon 1 · FRHospices Civils de Lyon · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug hypersensitivity reactions can lead to different clinical pictures depending on the underlying immunological mechanism. Diagnosis tests are already available to assess the most frequent drugs hypersensitivity reactions, which are mediated by specific IgE or T cells. However, it remains challenging to diagnose type 2 hypersensitivity reactions (T2HR), which can lead to severe cytopenia and liver failure. Here, we describe a case of T2HR to rasburicase, an uricolytic agent used to prevent tumor lysis syndrome. In this patient, sensitization was associated with the production of specific IgG able to bind to leukocytes. We found that patient NK cells were specifically activated in the presence of rasburicase and autologous serum, which led to exocytosis of lytic granules. This antibody-dependent cell cytotoxicity mechanism may lead to cytopenia observed in the patient. Moreover, this NK cell activation assay could be used to improve the diagnosis of a T2HR to rasburicase and, by extent, to other drugs. These data also suggest that NK cells could play an important role in the pathophysiological mechanism of T2HR.

Indexed as

Antibody-Dependent Cell CytotoxicityBiological AssayDrug HypersensitivityGout SuppressantsHumansKiller Cells, NaturalLymphocyte ActivationMaleMiddle AgedUrate OxidaseGout SuppressantsrasburicaseUrate OxidaseADCCantibody dependent cell cytotoxicitynatural killer cellsrasburicasetype 2 hypersensitivity

Identifiers

PMID29434608
PMCPMC5796899
OpenAlexW2792990073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.